MCAC Supports MADIT-II Criteria; EP Testing Scuttled As Stratification Tool
This article was originally published in The Gray Sheet
Executive Summary
Guidant's subgroup analysis demonstrating that non-inducible EP-tested patients showed lower mortality rates with ICDs over conventional therapy played a decisive factor in MCAC's endorsement of national coverage
You may also be interested in...
MCAC Referral Draft Guidelines Need Clarity, More Specificity – AdvaMed
Guidelines specifying how the public can best frame evidentiary questions used in MCAC review should be included in a 1CMS draft guidance stipulating criteria for when an NCD should be referred to the committee, AdvaMed maintains
MCAC Referral Draft Guidelines Need Clarity, More Specificity – AdvaMed
Guidelines specifying how the public can best frame evidentiary questions used in MCAC review should be included in a 1CMS draft guidance stipulating criteria for when an NCD should be referred to the committee, AdvaMed maintains
Guidant ICD, Stent Tactics Assuage Wall Street; Q1 Index Inches Up
Guidant allayed investor uncertainty over its future business strategy by winning a favorable MCAC reimbursement recommendation and executing a string of stent technology acquisitions, propelling the stock ahead 17.3% for the first quarter